Overexpression of eRF3a Promotes Cell Proliferation and Migration in Liver Cancer

Abstract

Objective

The eukaryotic release factor 3a (eRF3a), a member of the eukaryotic peptide chain release factor family, is overexpressed in several types of cancer. This study aims to investigate the biological role and mechanism of eRF3a in the progression of liver cancer.

Methods

Western blotting and RT-qPCR were used to detect the expression level of eRF3a in normal liver cells and liver cancer cells. The cell transfection experiments were performed to overexpress eRF3a levels in liver cancer cells HCCLM9 and Huh7, and then cell cycle and apoptosis experiments, Cell Counting Kit-8 (CCK8), plate cloning, and Transwell experiments were done to evaluate the function of eRF3a in the progression of liver cancer. The Western blotting was done to explore the mechanism of eRF3a promoting the development of liver cancer. Western blotting and RT-qPCR were used to detect the expression level of eRF3a in normal liver cells and liver cancer cells. The cell transfection experiments were performed to overexpress eRF3a levels in liver cancer cells HCCLM9 and Huh7, and then cell cycle and apoptosis experiments, Cell Counting Kit-8 (CCK8), plate cloning, and Transwell experiments were done to evaluate the function of eRF3a in the progression of liver cancer. The Western blotting was done to explore the mechanism of eRF3a promoting the development of liver cancer.

Results

eRF3a was significantly highly expressed in liver cancer cells, and its expression level was negatively correlated with the clinical prognosis of patients. In addition, in vitro experiments showed that eRF3a could promote the proliferation and migration of liver cancer cells through the ERK and JNK signaling pathways.

Conclusion

This study suggests that eRF3a may be a potential prognostic marker for liver cancer and act as an oncogene by activating JNK and ERK signaling; therefore, eRF3a may be a new target for the treatment of liver cancer.

Keywords

eukaryotic release factor 3a / liver cancer / migration / invasion

References

[1] LiuC, ChenK, ChenP. Treatment of Liver Cancer. Cold Spring Harbor Perspectives in Medicine, 2015, 5(9): a21535

[2] ZhouY, LiY, ZhouT, et al.. Dietary Natural Products for Prevention and Treatment of Liver Cancer. Nutrients, 2016, 8(3): 156

[3] GamblinTC, GellerDA. Downstaging hepatocellular carcinoma prior to liver transplantation. Liver Transpl, 2005, 11(12): 1466-1468

[4] KangN, HaiY, LiangF, et al.. Preconditioned hyperbaric oxygenation protects skin flap grafts in rats against ischemia/reperfusion injury. Mol Med Rep, 2014, 9(6): 2124-2130

[5] FongZV, TanabeKK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review. Cancer, 2014, 120(18): 2824-2838

[6] IvanovA, MikhailovaT, EliseevB, et al.. PABP enhances release factor recruitment and stop codon recognition during translation termination. Nucleic Acids Res, 2016, 44(16): 7766-7776

[7] Malta-VacasJ. Differential expression of the eukaryotic release factor 3 (eRF3/GSPT1) according to gastric cancer histological types. J Clin Pathol, 2005, 58(6): 621-625

[8] Malta-VacasJ, ChauvinC, GonçalvesL, et al.. eRF3a/GSPT1 12-GGC allele increases the susceptibility for breast cancer development. Oncol Rep, 2009, 21(6): 1551

[9] SunW, ZhangL, YanR, et al.. LncRNA DLX6-AS1 promotes the proliferation, invasion, and migration of non-small cell lung cancer cells by targeting the miR-27b-3p/GSPT1 axis. Onco Targets Ther, 2019, 12: 3945-3954

[10] XiaoR, LiC, ChaiB. miRNA-144 suppresses proliferation and migration of colorectal cancer cells through GSPT1. Biomedicine & Pharmacotherapy, 2015, 74: 138-144

[11] TianQ, TianR, LiuY, et al.. The role of miR-144/GSPT1 axis in gastric cancer. European review for medical and pharmacological sciences, 2018, 22(13): 4138-4145

[12] ChauvinC, Jean-JeanO. Proteasomal degradation of human release factor eRF3a regulates translation termination complex formation. RNA, 2007, 14(2): 240-245

[13] KrausS, BenardO, NaorZ, et al.. C-Src Is Activated by the EGF Receptor in a Pathway that Mediates JNK and ERK Activation by Gonadotropin-Releasing Hormone in COS7 Cells. Int J Mol Sci, 2020, 21(22): 8575

[14] LavoieJN, L’AllemamG, BrunetA, et al.. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem, 1996, 271(34): 20 608-20 616

[15] FangJY, RichardsonBC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol, 2005, 6(5): 322-327

[16] ChengZ, GuoJ, ChenL, et al.. Knockdown of EHF inhibited the proliferation, invasion and tumorigenesis of ovarian cancer cells. Mol Carcinog, 2016, 55(6): 1048-1059